Bml 277 , CHK2 kinase inhibitor

Get basic and detailed information about product. Buying link available


Catalog numberSIH-436-10MG
NameBml 277 , CHK2 kinase inhibitor
Size10 mg
Go to shop


Stock availabilitIn StockIn Stock
CAS number516480-79-8
DescriptionCHK2 kinase inhibitor
Molecular weight363,8 g/mol
Primary research fieldsCell Signaling, Cancer, Apoptosis, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors
Other nameChk2 Inhibitor II, Chk2 Inhibitor II hydrate, 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate
Product categorySmall Molecules
Product typeInhibitor
Chemical formulaC20H14ClN3O2
Purity pourcentage≥98% (TLC)
Soluble inSoluble in DMSO (20 mg/ml) or ethanol (20 mg/ml)
Physical appearanceOff-white solid
Storage recommendations-20ºC
Shipping recommendationsShipped Ambient
Safety informationClassification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
PubChem number9969021
Scientific contextBml 277 is a highly selective inhibitor of Chk2, making it a useful tool for dissecting the role of Chk2 in cellular signaling.
Bibliography1. Pereg Y., et al. (2006) Mol. Cell Biol. 26(18): 6819–6831.
Release date1-Oct-2014
PubMed numberRefer to PubMed
Tested applicationsTo be tested
Tested reactivityTo be tested
Representative figure legendChemical structure of BML 277 (SIH-436), a CHK2 kinase inhibitor. CAS #: 516480-79-8. Molecular Formula: C20H14ClN3O2. Molecular Weight: 363.8 g/mol. Chemical structure of BML 277 , a CHK2 kinase inhibitor (SIH-436). CAS # 516480-79-8. Molecular Formula: C20H14ClN3O2.
Warning informationNon-hazardous
Country of productionCanada
Total weight (kg)0.25
Net weight (g)0.01
Additional descriptionTissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.